Kornimate/medical-research-clean huggingface dataset:
impact of preoperative counseling and education in reducing anxiety levels in patients with gynecologic tumors

Conditions: Anxiety Disorders

Summary: the surgical procedure can be considered a transition in the patient's life. the transition can generate instability and produce negative effects, which may be temporary or permanent. failure to prepare people to deal with the unexpected, such as diagnosing a disease, such as cancer, and surgical necessity can be a frightening and frustrating experience, developing painful and distressing feelings, involving their family members as well.

a preoperative orientation process with potential benefits to the patient has been adopted for some surgical procedures. however, recently some surgical specialties such as orthopedics have been implemented in their routine a potentially modifiable conduct of the emotional trauma of a surgery, is the use of the preoperative advice and orientation, in order to attain an ability to increase the client's satisfaction, to facilitate the recovery, decrease the rate of complications without increasing reintegration, decrease hospitalization time and health costs without additional patient risk. there is a belief among surgeons that preoperative counseling and counseling is vitally important for a post-operative outcome. despite this, there is a paucity of well-conducted studies that examine the importance of the need for preoperative counseling with detailed information to analyze the yearnings and needs as well as the emotional impact. in addition, there are few studies evaluating the emotional impact and impact in the postoperative period in general of detailed preoperative counseling in patients with gynecological tumors submitted to laparotomy and minimally invasive surgery. for these reasons, this study aims to evaluate whether the application of detailed and clear preoperative counseling and education about the surgical procedure to be performed, as well as all the perioperative guidelines that involve the procedure versus the usual preoperative orientation and preoperative, can have an impact on the level of anxiety of the patient and the companion, as well as assess the degree of satisfaction of the companion.

Eligibility criteria:
inclusion criteria: * patients submitted to accessory treatment for tumors of the cervix, vulva, ovary or endometrium. * primary therapy, which may be radiotherapy or chemotherapy. * patients between the ages of 20 and 80 years. * patients submitted to a laparotomic or minimally invasive method (robotic and laparoscopic). * patients should be treated at the oncology gynecology service of the barretos cancer hospital. exclusion criteria: * patients treated at another oncology service previously. * patients who have already been treated for some other cancer in the past. * patients without a complete primary level and / or who can not read or write. * patients and / or family members who refuse to participate in the study. * patients who will be admitted to the icu.

Keywords: gynecological cancer anxiety pre-operative counseling
polyp measurement device

Conditions: Colorectal Cancer

Summary: colorectal cancer is the second-leading cause of cancer death in the united states. colorectal cancer screening is recommended to begin at age 50 years for most men and women at average risk for this disease. colonoscopy is a gold standard method of screening for colorectal cancer, allowing for the detection and removal of colorectal polyps, some of which can progress into malignancy. the literature has shown that the removal of polyps during a colonoscopy results in decreased incidence and mortality related to colorectal cancer. indeed, the last decade has shown a decline in colorectal cancer incidence and mortality in adults over age 50, largely due to increased colonoscopy screening. currently, the risk of a patient developing colorectal cancer and thus time intervals for colonoscopy surveillance post-polypectomy is determined by the number, pathology, and size of the polyps that are observed and removed during the colonoscopy procedure. current surveillance guidelines indicate the need for a shorter interval before the next colonoscopy for patients who have one or more polyps that are 10mm or larger. in addition, different polypectomy techniques are indicated for the treatment of polyps less than 20mm in size. for example, cold forceps may be appropriate for removal of 1mm to 2mm polyps, cold snare for polyps less than 10mm, and hot-snare resection for polyps 10mm to 19mm. yet, while the number and pathology of polyps are easily obtained and verified, it is standard practice for the size of a polyp to be assessed through endoscopist optical visualization alone, without use of an objective device or standard by which to measure it. often, the endoscopist will compare the size of the polyp to the size of the snare loop to estimate and document the size of the polyp(s). however, with the size of a polyp being a major indicator of malignant potential as well as an indicator of appropriate polypectomy technique and surveillance intervals, a device with which to take and document accurate and objective measurements of polyps during colonoscopy holds the potential for health benefits. in addition to having a potential clinical benefit for each patient in terms of polypectomy and surveillance intervals, as an objective indicator of polyp size, this technique also holds promise for use in future studies that evaluate polyp size as an indicator of potential malignancy (or future malignancy) and for use by national clinical guidelines committees who may utilize these objective data to update future screening and surveillance recommendations.


Eligibility criteria:
inclusion criteria: * individuals age 50-85 years old, who require an outpatient screening or surveillance colonoscopy * ability to give consent exclusion criteria: * pregnancy * inflammatory bowel disease
study on patterns of care in mild asthmatic patients

Conditions: Asthma

Summary: the prime study is an observational, real world evidence study designed to collect the type of treatments that are currently prescribed to patients with mild asthma and to collect relevant clinical data that could reflect the control of the disease over a 6-month observational period according to the standard clinical practice.

outpatients attending the hospital clinics/study centres will be recruited. patients with mild asthma treated by step 1 or step 2 treatments according to gina report will be recruited. a total of approximately 1200 patients will be enrolled. patients will be followed-up during a 6-month observational period according to standard practices.

Eligibility criteria:
inclusion criteria: * adult subject (aged ≥ 18 years) up to 75 years * subject with confirmed asthma diagnosis * subject in treatment for mild asthma with step 1 or step 2 according to gina report * subject with written privacy and study informed consent exclusion criteria: * subject enrolled in experimental (interventional) clinical trials, or receiving experimental treatments in the prior 3 months * known pregnant or breast-feeding subject * subject unable to understand and autonomously fill in questionnaires * subject unable to use electronic devices to fill in e-diary, or without compatible electronic devices with access to the internet * subject who had asthma exacerbation(s) in the past 4 weeks prior to study entry * subject with confirmed chronic obstructive pulmonary disease
feasibility of cetuximab associated with concomitant radio-chemotherapy in patients with locally advanced non small cell lung cancer

Conditions: Non-Small-Cell Lung Carcinoma

Summary: phase ii, randomised, controlled, non comparative study with 2 parallel groups: * arm a: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemotherapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy. * arm b: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.


Eligibility criteria:
inclusion criteria: * non-small-cell lung cancer cytologically or histologically proved * stage iii an2 inoperable or non resectable * presence of at least one one dimension measurable target (at least 10 mm with spiral tomodensitometry) * possibility to include all targets in one irradiation field * age of 18 to 70 * patients non previously treated * performance status 0 or 1 * loss of weight ≤10% in the 3 last months * neutrophil ≥ 1500/mm3 and platelets ≥ 100000/mm3 * creatinine clearance ≥ 60 ml/min * total bilirubin ≤ 1,5n and asat alat ≤ 2,5n * respiratory function normal: vems ≥ 40% theorical, dlco/va ≥ 50% theorical and pao2 ≥ 60 mmhg * signed inform consent form * compliance to radiotherapy 66 gy with dosimetry v20 ≤ 35% and pulmonary mean dose≤20 gy exclusion criteria: * pretreated bronchial carcinoma, excepted endoscopic deobstruction * operable bronchial carcinoma * small cell lung cancer, composite cancer, neuroendocrine cancer, broncho alveolar cancer * superior vena cava syndroms * puncturable pleural effusion * metastatic lung cancer * stage iiib cancer with neoplastic pericarditis * previous thoracic irradiation * severe cardiac disease in the 12 months before inclusion * interstitial lung disease * anti-egfr and anti-vegf treatments * hypersensitivity to murine proteins and allergies to protocol drugs * uncontrolled infectious state * hiv patient * corticoid definitive contraindication * péripheric neuropathy grade≥2 * neurologic, psychiatric and organic disorder * past or concomitant cancer excepted treated skin baso-cellular cancer or in situ cervical cancer, or any cancer only surgically treated for 5 years * breastfeeding woman
allosure lung assessment and metagenomics outcomes study

Conditions: Lung Transplant Infection; Lung Transplant; Complications; Lung Transplant Failure and Rejection

Summary: alamo is a prospective, multi-center, perspective, registry of patients receiving lungcare™ (allosure®-lung, allomap lung, and histomap) for surveillance post-transplant. this study aims to evaluate the diagnostic performance characteristics of allosure lung (dd-cfdna) to detect a spectrum of rejection (acr, amr) and allograft infection (bacterial, viral, fungal, mycobacterial, parasitic).

this is a prospective, multicenter, observational registry of lung transplant recipients receiving lungcare (allosure-lung, allomap lung, and histomap) surveillance testing. patients will be recruited based on utilization of surveillance testing with lungcare, as deemed appropriate for their care post-transplant. patients deemed eligible for the study by their physician will be invited to participate during their usual care visit. enrolled patients will receive evaluations and treatment for their lung transplant according to their health care provider and clinical practice at each study site. treatment and follow-up visits will be determined by the treating physician. information related to surveillance testing, selected clinical outcomes, and treatments received for managing the lung transplant recipients will be collected from medical records. the product laboratory services guide(s) will be provided as a reference. patient data (including diagnosis and biopsy outcomes) will be drawn from the patients' medical records. this data will be recorded by the site study personnel via a web-based electronic data collection (edc) system every month. the study is designed to observe the clinical use of lungcare and patient outcomes in a cohort of lung transplant recipients managed with lungcare. this cohort design is selected because it is efficient and effective to evaluate the real-world robust performance of lungcare on patient management and outcomes that can be generalized to the intended use population. a well-designed observational cohort study that includes a large number of patients with long-term follow-up may provide robust results with several advantages, such as gathering data regarding sequence of events to assess causality; examining multiple outcomes for a given lungcare use; calculating rates of biopsy and rejection; and operational efficiency.

Eligibility criteria:
inclusion criteria: 1. unilateral or bilateral, deceased-donor, initial or re-transplant 2. ≤ 90 days post-transplant 3. ability to understand and provide informed consent and adhere to laboratory surveillance schedule 4. patients who have lungcare initiated within 30 days of signing the informed consent form exclusion criteria: 1. multi-organ transplants 2. pregnancy 3. active malignancy
mechanism of sarcopenia in heart failure

Conditions: Heart Failure; Sarcopenia; Cachexia

Summary: the aim of the study is to provide information on the interaction between socioeconomic factors, daily physical activity, nutrition and lifestyle on loss of muscle mass and muscle function in patients with heart failure.

a total of 200 consecutive heart failure patients will be included and 50 age and sex-matched individuals with no history of cardiovascular disease will serve as controls. baseline variables of body composition, physical capacity, daily physical activity, nutritional status, quality of life, socioeconomic status and insulin resistance will be obtained along with a skeletal muscle tissue biopsy and blood samples for laboratory analyses. baseline variables from heart failure patients will be compared to healthy controls. patients and controls will be invited to follow-up visits at 12 and 36 months. changes in baseline variables will be analyzed. events will be identified through national registries.

Eligibility criteria:
inclusion criteria: 1. ability to provide valid informed consent. 2. heart failure with preserved, mid-range or reduced ejection fraction (nyha i-iv) according to european society of cardiology guidelines. exclusion criteria: 1. cancer requiring treatment (e.g. prostate cancer on watchful waiting does not exclude patients). 2. severe musculoskeletal or neurological disability. 3. severe lung disease with a forced expiratory volume 1 \< 40% of predicted. treatment with anticoagulants (warfarin, apixaban, edoxaban, dabigatran and rivaroxaban) is an exclusion criterion for muscle biopsy. patients with anticoagulant treatment will be invited to participate in the study without muscle biopsy. 4. other comorbidities that prevent the patient from participating in the study examinations as judged by the investigator.

Keywords: heart failure sarcopenia cachexia
tranexamic acid use and blood loss in total hip arthroplasty

Conditions: Tranexamic Acid Use; Blood Loss

Summary: the purpose of this study is to determine the need for a blood transfusion during surgery and to evaluate the levels of certain proteins in the blood when given tranexamic acid.

a review of the medical record between january 01 2013 to july 1st 2015 will be used to determine if the hypothesis that patients receiving tranexamic acid will have a lower need for blood transfusion and there are changes in the levels of the proteins essential for healthy oxygen transport throughout the body is correct. tranexamic acid is a medication which may help wounds to stop bleeding more quickly. participants are not expected to receive any direct benefits from participating in this study. only a small risk of private patient medical information being exposed is anticipated. the results of this study will help surgeons and the medical community to better understand the uses of this type of drug and its possible role in benefiting hip replacement patients during and following surgery.

Eligibility criteria:
inclusion criteria: * adult patients 18 years of age and older * surgical patients who underwent primary total hip arthroplasty (tha) * surgical patients who underwent revision tha * preoperative hemoglobin values (n) 11 g/dl * normal international normalized ratio (inr), prothrombin time (pt), partial thromboplastin time (ptt) values exclusion criteria: * - allergy to tranexamic acid * bilateral tha * history of ischemic heart disease * severe chronic heart failure * hepatic dysfunction * chronic renal failure * on hemodialysis * cerebral infarction * history of seizure * bleeding disorder * anticoagulant or aspirin-like medication and long acting nsaid medication * short acting nsaid's were discontinued at least 24 hrs before surgery
covid vaccine immunity in kidney transplant recipients

Conditions: End Stage Renal Disease; Kidney Transplant; Complications

Summary: 50 end-stage renal disease (esrd) patients whom have had at least 2 doses of messenger ribonucleic acid (mrna) vaccine, and undergoing transplantation at the university of alabama at birmingham (uab) will be enrolled. the third mrna vaccine will be given 3 months post transplant, and the 4th mrna vaccine will be given 3 months following this. blood samples will be collected and shipped to viracor on day of transplant, and at months 1, 3, 4, 6, and 12 for spike protein and t cell assay.

50 esrd patients on peritoneal dialysis or hemodialysis or not on immunosuppression, no prior transplant, no known history of covid infection, whom have had at least 2 doses of mrna vaccine, and undergoing transplantation at uab will be enrolled, after signing the informed consent. the third mrna vaccine will be given 3 months post transplant, and the 4th mrna vaccine will be given 3 months following this. blood samples will be collected and shipped to viracor on day of transplant, and at months 1, 3, 4, 6, and 12 for spike protein and t cell assay.

Eligibility criteria:
inclusion criteria: * end stage renal disease patients on peritoneal dialysis or hemodialysis or not on immunosuppression * no prior transplant * no known history of covid infection * had at least 2 doses of mrna covid vaccine * undergoing transplantation at the university of alabama at birmingham * multi-organ transplant allowed exclusion criteria: * active covid infection * participant is not vaccinated against covid

Keywords: covid-19 kidney kidney transplant end stage renal disease mrna vaccine
which needs for premature new-born babies' parents facing environmental and social difficulties ?

Conditions: Preterm Birth

Summary: this study aims to understand parents' needs regarding social difficulties faced in a child's preterm birth context.

* from parents collected during semi-structured interviews. * to highlight the social, environmental and economic difficulties that parents have encountered in the context of the premature birth of their child (before birth, during hospitalization and return home). * determine the possible help they need in the psychosocial and environmental field. * difficulties of the parents we expected: * pre-existing child birth: poor socio-economic environment, unstable social, family and / or occupational status, poorly followed pregnancy, etc. * after the birth: professional break-up, custody of other children of the siblings, balance of the couple, financial loss, isolation, transportation problems to get to the hospital, etc. * needs we expected : * before birth: measures to prevent prematurity, social and/or psychological support, information, etc. * after the birth: support of the entourage, interview with a social worker, help to come in hospital, help to live near the hospital, parental leave, project and long-term support, doctor referred, relationship with professionals in ambulatory (psychologist, infant and maternal protection ...), preparation of the arrival of the child at home +/- home improvement, etc.

Eligibility criteria:
inclusion criteria: * parents (father or mother ) of a premature new-born baby (\< 37 sa) hospitalised in besancon university hospital at birth. exclusion criteria: * parents \< 18 years old * refusing to participate
exercise, pne and cognitive training in individuals with chronic low back pain

Conditions: Chronic Low-back Pain

Summary: this study aims of to investigate whether combining cognitive training to exercise and pain neuroscience education will contribute to reduction of pain and associated symptoms (i.e., catastrophizing, fear of movement, disability) in individuals with low back pain (lbp).

this study aims of to investigate whether combining cognitive training to exercise and pain neuroscience education (pne) will contribute to reduction of pain and associated symptoms (i.e., catastrophizing, fear of movement, disability) in individuals with low back pain (lbp). it will have three arms of which will receive exercise, pne and/or cognitive training for 8 weeks (group i - exercise and pne; group ii - exercise, pne and cognitive training; group iii - cognitive training). participants will be assessed for pain characteristics, psychological, and cognitive aspects at baseline, post-intervention and at 3 months follow-up.

Eligibility criteria:
inclusion criteria: * have chronic idiopathic lbp * report pain intensity of at least 2 out of 10 on the numeric pain rating scale * 18 to 64 years old * be able to read, write and speak portuguese * asses to personal computer and internet for those receiving cognitive training exclusion criteria: * individuals receiving any chronic treatment for their pain * symptoms of peripheral nervous system pathology (e.g., motor weakness and sensory disturbance); * a diagnosis of an ongoing neurological disease with peripheral or central nervous system involvement or relevant sequela; * having a diagnosis of ongoing psychiatric disease * having relevant cognitive impairment as assessed by montreal cognitive assessment (moca).

Keywords: cognitive training exercise chronic low back pain pain neuroscience education
long-term follow-up of glutamic acid decarboxylase (gad) gene transfer in parkinson's disease

Conditions: Parkinson Disease

Summary: the objective of this study is to evaluate the long-term safety of aav-gad delivered bilaterally to the subthalamic nuclei (stn) in participants with parkinson's disease.

the duration of individual participation in this study will be approximately 54 months for participants who received aav-gad in study mgt-gad-025 and approximately 60 months for participants who received sham surgery in study mgt-gad-025.

Eligibility criteria:
inclusion criteria: * previously enrolled in study mgt-gad-025. exclusion criteria: * none